Carnosic acid in rosemary extract may enhance skin repair and promote hair follicle regeneration. It could be used alone or with verteporfin for scarless healing after dermal wounding.
Fatty acid metabolic signaling can activate epithelial stem cells for hair regeneration. Oleic and palmitoleic acids showed the best results, but practical application on humans remains uncertain.
Male-pattern baldness might increase UVB exposure on the scalp, potentially affecting vitamin D and skeletal health. The hypothesis is debated, with some seeing it as a minor benefit in specific contexts.
RU58841 may pose cancer risks due to its antiandrogen properties and lack of long-term safety data. Using it is considered a high-risk experiment with unknown potential for harm.
Betacarotene's effect on hair loss is discussed, with concerns about excessive vitamin A. The user also questions if 15mg melatonin impacts vitamin A levels.
Verteporfin is being discussed for its potential to regrow hair and heal scars, possibly aiding hair transplants or replacing them. Some users are skeptical about its effectiveness, while others suggest combining it with microneedling for better results.
PP405 shows promise in activating dormant hair follicles and increasing hair counts but lacks detailed efficacy data compared to minoxidil and finasteride. Opinions are mixed, with some optimism and skepticism about its effectiveness.
Concerns about dermarolling potentially causing collagen breakdown and cancer, with skepticism about the claims due to lack of scientific evidence. Users express doubts and discuss the validity of the article's claims.
PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.
Tazarotene shows potential as a standalone treatment for hair regrowth by stimulating new hair follicle formation and promoting angiogenesis, similar to microneedling effects. It can be used topically without minoxidil, but users should start with a low concentration to avoid irritation.
PP405 trials have completed phase 2a, showing promising results with a 31% stat for hair density increase, and are moving directly to phase 3. Detailed results will be presented at a medical conference in 2026.
A user observed orange fluorescence on their nose and hair under a black light, indicating Cutibacterium acnes, which may contribute to hair loss alongside androgenic alopecia. A suggestion was made to use coal tar shampoo to address the issue.
Exosomes combined with fractional picosecond laser treatment were effective in treating androgenetic alopecia and promoting repigmentation in white hair patches. The role of exosomes in hair repigmentation, particularly in conditions like poliosis, is not well-studied.
Topical finasteride may have higher systemic absorption and lower efficacy when using a Propylene Glycol/Ethanol formulation compared to the hydroxypropyl chitosan (HPCH) formulation. The safety profile of topical finasteride relies heavily on the HPCH formulation, and using standard solutions might lead to different pharmacokinetics.
DHT causes hair loss by driving cells into senescence, and a polyphenol in black chokeberry may reverse this. A product using this theory is being considered for use alongside finasteride, minoxidil, and microneedling.
The conversation discusses an experiment involving hair loss treatments, including the use of Verteporfin, KY19382, dutasteride, oral and topical minoxidil, AHK-Cu, and microneedling. The experiment aims to test the effectiveness of these treatments in promoting hair growth and healing without scarring, with updates planned every few months.
Concerns about the integrity of Dr. Melissa Toyos' marketing for Verteporfin treatment, suggesting photos may be digitally altered. Users express skepticism about the treatment's promotion and results.
A quercetin-encapsulated and polydopamine-integrated nanosystem (PDA@QLipo) shows promise for treating androgenetic alopecia by reshaping the perifollicular microenvironment, outperforming minoxidil in hair regeneration. The nanosystem promotes cell proliferation, hair follicle renewal, and recovery by scavenging reactive oxygen species and enhancing neovascularity.
PP405 may damage hair follicles if used long-term, suggesting cycling might be necessary. Combining it with finasteride could help maintain hair growth.
GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.
The user noticed thicker hair at their hairline after using a skincare serum containing GHK-CU, despite using pyrilutamide for hair loss without success. They plan to apply the serum more broadly to see if it improves hair growth.
AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.
Topical minoxidil may cause skin aging effects like wrinkles and dark circles, possibly due to its alcohol content, while oral finasteride is reported to make users look younger. Switching to oral minoxidil or using moisturizers might help reduce these skin issues.
PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.
The conversation discusses potential causes of pigmentation around hair follicles, suggesting sebum buildup, autoimmune conditions, or dermatitis. Treatments mentioned include finasteride, dutasteride, and an anti-inflammatory diet, with a recommendation to consult a doctor for a proper diagnosis.
The user reports noticeable hair growth after 5 weeks using finasteride, minoxidil, dermarolling, and ketoconazole. They seek confirmation of their progress and question if they are a hyper responder.
OP injured their temple using derma rolling and tretinoin, causing peeling and potential hair follicle damage. Users suggest the injury might be permanent, possibly resulting in scar tissue where hair won't grow.
The conversation discusses using a TCA 35% chemical peel on the scalp to potentially improve hair growth by addressing fibrosis and enhancing the effectiveness of topical treatments. The user also mentions trying microneedling and other methods like topical metformin and dutasteride for hair regrowth.